Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer

References

• MillerKDSiegelRLLinCCCancer treatment and survivorship statistics, 2016CA Cancer J Clin201666427128927253694
   PubMed Web of Science ®Google Scholar
• BrayFFerlayJSoerjomataramIGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin201868639442430207593
   PubMed Web of Science ®Google Scholar
• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• BadarFMahmoodSEpidemiology of cancers in Lahore, Pakistan, among children, adolescents and adults, 2010-2012: a cross-sectional study part 2BMJ Open2017712e016559
   PubMed Web of Science ®Google Scholar
• DesantisCELinCCMariottoABCancer treatment and survivorship statistics, 2014CA Cancer J Clin201464425227124890451
   PubMed Web of Science ®Google Scholar
• TeicherBAAnticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval2nd edGermanySpringer Science & Business Media2013
   Google Scholar
• PrattWBThe Anticancer Drugs1994 edUSAOxford University Press1994
   Google Scholar
• SenkusEKyriakidesSOhnoSPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201526suppl 5v8v3026314782
   PubMed Web of Science ®Google Scholar
• GradisharWJAndersonBOBalassanianRInvasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncologyJ Natl Compr Canc Netw201614332435426957618
   PubMed Web of Science ®Google Scholar
• GradisharWAndersonBBalassanianRNCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version 1.20172017 Available from: https://wwwnccnorg/store/login/loginaspx?ReturnURL=https://wwwnccnorg/professionals/physician_gls/pdf/breastpdfAccessed December 17, 2018
   Google Scholar
• GradisharWJAndersonBOBalassanianRNCCN Guidelines Insights: Breast Cancer, Version 1.2017J Natl Compr Canc Netw201715443345128404755
   PubMed Web of Science ®Google Scholar
• RunowiczCDLeachCRHenryNLAmerican cancer society/American society of clinical oncology breast cancer survivorship care guidelineCA Cancer J Clin2016661437326641959
   PubMed Web of Science ®Google Scholar
• HoffmannTCorrêa-FissmerMDuarteCSNazárioRFBarrancoABSOliveiraKWKPrevalence of dermatological complaints in patients undergoing treatment for breast cancerAn Bras Dermatol201893336236729924229
   PubMed Web of Science ®Google Scholar
• HughJHansonJCheangMCBreast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trialJ Clin Oncol20092781168117619204205
   PubMed Web of Science ®Google Scholar
• KumarSChoudharySSinghNSettyMCombination of natural drugs: an emerging trend in cancer chemotherapyJ Drug Deliv Ther20122397105
   Google Scholar
• LiSYuanSZhaoQWangBWangXLiKQuercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of itBiomed Pharmacother201810044144729475141
   PubMed Web of Science ®Google Scholar
• TangJZhangRGuoMNucleosome-inspired nanocarrier obtains encapsulation efficiency enhancement and side effects reduction in chemotherapy by using fullerenol assembled with doxorubicinBiomaterials201816720521529571055
   PubMed Web of Science ®Google Scholar
• US-NCICTCAE v5.0 Clean, Tracked, and Mapping Document (Excel)2017 Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50Accessed October 07, 2018
   Google Scholar
• The American Society of Health-System Pharmacists IDoxorubicin2012 Available from: https://medlineplus.gov/druginfo/meds/a682221.htmlAccessed October 07, 2018
   Google Scholar
• The American Society of Health-System Pharmacists IDocetaxel20142018 Available from: https://medlineplus.gov/druginfo/meds/a696031.htmlAccessed October 07, 2018
   Google Scholar
• FrèresPBouznadNServaisLVariations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patientsBMC Cancer201818110229378531
   PubMedGoogle Scholar
• DolciADominiciRCardinaleDSandriMTPanteghiniMBiochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for useAm J Clin Pathol2008130568869518854260
   PubMed Web of Science ®Google Scholar
• ChanSFriedrichsKNoelDProspective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancerJ Clin Oncol19991782341235410561296
   PubMed Web of Science ®Google Scholar
• ThavendiranathanPPoulinFLimKDPlanaJCWooAMarwickTHUse of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic reviewJ Am Coll Cardiol20146325 Pt A2751276824703918
   PubMed Web of Science ®Google Scholar
• SchvartzmanPRFuchsFDMelloAGColiMSchvartzmanMMoreiraLBNormal values of echocardiographic measurements. A population-based studyArq Bras Cardiol2000752111114
   Google Scholar
• MohriJKatadaCUedaMPredisposing factors for chemotherapy-induced nephrotoxicity in patients with advanced esophageal cancer who received combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracilJ Transl Int Med201861323729607302
   PubMed Web of Science ®Google Scholar
• BeutlerEWaalenJThe definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?Blood200610751747175016189263
   PubMed Web of Science ®Google Scholar
• US-Department-of-Health-and-Human-ServicesCommon Terminology Criteria for Adverse Events (CTCAE) version 4.0National Cancer Institute2009095410
   Google Scholar
• MartínMLluchASeguíMAToxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimenAnn Oncol20061781205121216766587
   PubMed Web of Science ®Google Scholar
• BayoJAviñóVToscanoFJiménezFToxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxisBreast J201824446246729205665
   PubMed Web of Science ®Google Scholar
• BonadonnaGBrusamolinoEValagussaPCombination chemotherapy as an adjuvant treatment in operable breast cancerN Engl J Med197629484054101246307
   PubMed Web of Science ®Google Scholar
• JonesSESavinMAHolmesFAPhase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophos-phamide as adjuvant therapy for operable breast cancerJ Clin Oncol200624345381538717135639
   PubMed Web of Science ®Google Scholar
• von MinckwitzGRaabGCaputoADoxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast GroupJ Clin Oncol200523122676268515837982
   PubMed Web of Science ®Google Scholar
• NabholtzJMFalksonCCamposDDocetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trialJ Clin Oncol200321696897512637459
   PubMed Web of Science ®Google Scholar